ONCOLYTICS BIOTECH INC | CIK:0001129928 | 3

  • Filed: 3/19/2018
  • Entity registrant name: ONCOLYTICS BIOTECH INC (CIK: 0001129928)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/0001129928-18-000028-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/oncyf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001129928
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory

    Other Expenses and Adjustments

    We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.

    2017
    $
    2016
    $
    2015
    $
    Included in research and development expenses:






    Realized foreign exchange (gain) loss
    (120,794
    )
    104,851

    238,709

    Unrealized non-cash foreign exchange loss (gain)
    55,538

    67,109

    (816,319
    )
    Non-cash share based compensation
    230,141

    233,919

    257,016








    Included in operating expenses






    Amortization of property and equipment
    90,768

    162,233

    180,411

    Non-cash share based compensation
    348,562

    172,159

    172,521

    Office minimum lease payments
    231,509

    148,600

    196,601